PTGS2 and hepatocellular carcinoma: In 2020, a study evaluated the association between cyclooxygenase inhibitors—including NSAIDs and selective COX-2 inhibitors—and the risk of developing hepatocellular carcinoma (HCC) in patients with chronic hepatitis B infection.